跳至主要内容
临床试验/NCT01195675
NCT01195675已完成1 期

Assessment of the Effect of 25 mg and 200 mg of BI 10773 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Five-period Crossover Phase-I-study With Moxifloxacin as Positive Control

Boehringer Ingelheim1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2010年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
30
试验地点
1
主要终点
Empa 25mg: Mean QTcN Change From Baseline Between 1 and 4 Hours After Dosing

研究概览

简要总结

The objective of this study is to demonstrate that BI 10773 does not prolong the QT(c) interval more than placebo

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

BI 10773

Experimental

single oral (high and low) dose per subject

干预措施: BI 10773 (low) (Drug)

BI 10773

Experimental

single oral (high and low) dose per subject

干预措施: BI 10773 (high) (Drug)

Placebo

Placebo Comparator

2 single oral doses per subject

干预措施: BI 10773 Placebo (Drug)

Moxifloxacin

Active Comparator

single oral dose per subject

干预措施: Moxifloxacin (Drug)

结局指标

主要结局

Empa 25mg: Mean QTcN Change From Baseline Between 1 and 4 Hours After Dosing

时间窗: 60 minutes (min), 50min and 40 min before the first dose and 1 hour (h), 1.5h, 2h, 2.5h, 3h and 4h after the first dose

Mean QTcN (heart rate-corrected QT interval, using a study population-based approach) from the ECGs obtained between 1h to 4h following drug administration minus the mean QTcN from the baseline electrocardiogram (ECGs) obtained pre-dose at each visit, for empa 25mg. Note, the treatment means presented are actually adjusted means.

Empa 200mg: Mean QTcN Change From Baseline Between 1 and 4 Hours After Dosing

时间窗: 60 minutes (min), 50min and 40 min before the first dose and 1 hour (h), 1.5h, 2h, 2.5h, 3h and 4h after the first dose

Mean QTcN (heart rate-corrected QT interval, using a study population-based approach) from the ECGs obtained between 1h to 4h following drug administration minus the mean QTcN from the baseline ECGs obtained pre-dose at each visit, for empa 200mg. Note, the treatment means presented are actually adjusted means.

次要结局

  • Empa 25 mg: Mean QTcN Change From Baseline Between 30 Minutes and 24 Hours After Dosing(60 minutes (min), 50min and 40 min before the first dose and 30min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h and 24h after the first dose)
  • Empa 200 mg: Mean QTcN Change From Baseline Between 30 Minutes and 24 Hours After Dosing(60 minutes (min), 50min and 40 min before the first dose and 30min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h and 24h after the first dose)
  • Mean QTcN Change From Baseline Between 2 and 4 Hours After Dosing(60 minutes (min), 50min and 40 min before the first dose and 2 hour (h), 2.5h, 3h and 4h after the first dose)
  • Empa 25mg: Change From Mean Baseline in QTcN at Each Time Point Between 30 Minutes and 24 Hours After Dosings(60 minutes (min), 50min and 40 min before the first dose and 0.5 hour (h), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h and 24h after the first dose)
  • Empa 200mg: Change From Mean Baseline in QTcN at Each Time Point Between 30 Minutes and 24 Hours After Dosings(60 minutes (min), 50min and 40 min before the first dose and 0.5 hour (h), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h and 24h after the first dose)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验